-
2
-
-
18544397596
-
Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: Methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone
-
Kim DY, Lee KW, Yun T, et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33: 608-612, 2003.
-
(2003)
Jpn J Clin Oncol
, vol.33
, pp. 608-612
-
-
Kim, D.Y.1
Lee, K.W.2
Yun, T.3
-
3
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
4
-
-
59649105302
-
EGFR-TKI and lung adenocarcinoma with CNS relapse: Interest of molecular follow-up
-
Ruppert AM, Beau-Faller M, Neuville A, et al. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J 33: 436-440, 2009.
-
(2009)
Eur Respir J
, vol.33
, pp. 436-440
-
-
Ruppert, A.M.1
Beau-Faller, M.2
Neuville, A.3
-
5
-
-
18844417090
-
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
-
Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103: 2344-2348, 2005.
-
(2005)
Cancer
, vol.103
, pp. 2344-2348
-
-
Omuro, A.M.1
Kris, M.G.2
Miller, V.A.3
-
6
-
-
30944434263
-
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation
-
Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol 3: 50-57, 2006.
-
(2006)
Nat Clin Pract Oncol
, vol.3
, pp. 50-57
-
-
Choong, N.W.1
Dietrich, S.2
Seiwert, T.Y.3
-
7
-
-
70449584901
-
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib
-
Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4: 1415-1419, 2009.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1415-1419
-
-
Katayama, T.1
Shimizu, J.2
Suda, K.3
-
8
-
-
83755230500
-
-
TNM Classification of Malignant Tumors. Sobin LH, Wittekind C, Eds. Wiley and Sons, New York
-
TNM Classification of Malignant Tumors. Sobin LH, Wittekind C, Eds. Wiley and Sons, New York, 2002: 97-103.
-
(2002)
, pp. 97-103
-
-
-
9
-
-
33749046899
-
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
-
Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24: 4517-4520, 2006.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4517-4520
-
-
Jackman, D.M.1
Holmes, A.J.2
Lindeman, N.3
-
10
-
-
67349186396
-
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
-
Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65: 80-84, 2009.
-
(2009)
Lung Cancer
, vol.65
, pp. 80-84
-
-
Yi, H.G.1
Kim, H.J.2
Kim, Y.J.3
-
11
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]
-
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
-
12
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
-
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003.
-
(2003)
JAMA
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
-
13
-
-
18144400958
-
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis
-
Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 64: 1625-1627, 2005.
-
(2005)
Neurology
, vol.64
, pp. 1625-1627
-
-
Omuro, A.M.1
Lallana, E.C.2
Bilsky, M.H.3
Deangelis, L.M.4
|